Skip to content
TrialScanner

NCT02998047

A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma

Phase 1TerminatedATNMLead

Registry record

Lead sponsor
Actinium Pharmaceuticals
Conditions
Refractory Multiple Myeloma
Primary completion
May 2020Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT02998047 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.